Day: February 22, 2021

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the Phase 3 clinical trial of OTIVIDEX in patients with Ménière’s disease did not achieve the primary endpoint, which was the count of definitive vertigo days (DVD) in Month 3 for OTIVIDEX vs. placebo for the intent-to-treat (ITT) population (n = 148; p value = 0.312) using the Negative Binomial Model. This analysis did achieve statistical significance for the per protocol (PP) population (n = 136; p value = 0.031). These results were similar using the Generalized Poisson model (p value = 0.340 for ITT and p value = 0.030 for PP).“We are disappointed by the top-line results for the primary intent-to-treat population and are undertaking...

HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) — TC PipeLines, LP (NYSE: TCP) (the Partnership or TC PipeLines) today reiterated its support of the pending merger with TC Energy Corporation (TSX, NYSE: TRP) (TC Energy).In reaffirming its support of the pending merger, the Partnership notes that:TC PipeLines unitholders will benefit from a more stable, diversified and attractive value creation opportunity in TC Energy: TC PipeLines unitholders will become TC Energy shareholders, providing the opportunity to participate in the growth of the post-merger company. TC Energy’s valuation has proven to be more resilient during the recent challenging environment than that of TC PipeLines.The transaction is expected to enhance potential growth for the Partnership: TC Energy has greater access to capital, including a larger North American investor...

PREVENT-19 enrolls 30,000 volunteers across 118 sites in the U.S. and MexicoGAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of the company’s COVID-19 vaccine. Novavax has previously reported positive interim efficacy results of NVX-CoV2373, its recombinant protein-based vaccine candidate, in an ongoing Phase 3 clinical trial taking place in the United Kingdom.“The full enrollment of PREVENT-19 is another important step in building a body of evidence to demonstrate that NVX-CoV2373 will be safe and effective across diverse, representative populations,”...

PLANO, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs pre-market on March 1, 2021.Reata’s management will host a conference call on March 1, 2021 at 8:30 am ET. The conference call will be accessible by dialing (866)270-1533 (toll-free domestic) or (412)317-0797 (international) using the access code: 10152707. The webcast link is https://event.on24.com/wcc/r/3023787/38597EBB280C48468322B7487DECE1EF.Fourth quarter and full year 2020 financial results to be discussed during the call will be included in an earnings press release that will be available on the company’s website shortly before the call...

STAMFORD, Conn., Feb. 22, 2021 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in the following upcoming investor conferences:Cowen 41st Annual Health Care Conference on Wednesday, March 3 from 11:00-11:30 a.m. ETH.C. Wainwright Global Life Sciences Conference on Tuesday, March 9 (presentation available on-demand)Barclays Global Healthcare Conference on Wednesday, March 10 from 3:35-4:00 p.m. ETWebcasts of these events can be accessed by visiting the “Events & Presentations” page within the Investors & Media section of the SpringWorks website at https://ir.springworkstx.com. A replay of the webcasts will be available...

Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin Second Quarter 2021, with Data Expected by the End of 2021An Investigator-Initiated Trial Will Run in ParallelYAVNE, Israel, Feb. 22, 2021 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced the initiation of a new clinical development program to evaluate its drug product candidate MWPC005 in patients with non-melanoma skin cancer. MediWound recently submitted a protocol to the FDA for a phase I/II clinical study of MWPC005 for the treatment of basal cell carcinoma (BCC) and is preparing to initiate this study in the United States in the second quarter of 2021. A phase II investigator-initiated trial of MWPC005 in non-melanoma...

Starting today, Serstech offers its customers the option to rent complete solutions for chemical identification. The solutions include instruments, substance libraries, software and accessories and allow police, border control and other customer groups to quickly increase their capabilities and efficiency.The additional values a rental solution provides are flexibility, reduced risk, no upfront investment and a much faster way to get access to modern technology. Before Serstech Rental, it could take years from when a customer became interested in Raman until they had the instruments deployed in the field. With the much quicker and far less complex rental option, the same customer will have access to state-of-the-art Raman solutions within weeks.“The main obstacle for customers who want to buy a Raman device today is the size of the initial...

EVLI BANK PLC STOCK EXCHANGE RELEASE FEBRUARY 22, 2020, 1.15 PM. (EET/EEST)The Board of Directors of Evli Bank Plc has in its meeting on January 22, 2021 approved a request of a shareholder to convert 7,600 Series A shares of Evli Bank Plc to Series B shares in accordance with Article 4 in the Articles of Association.As a result of the conversion of shares, the company’s amount of Series A shares totals 14,627,664 and the amount of Series B shares totals 9,481,756. The conversion does not affect the total amount of shares which is 24,109,420. The number of votes of the company’s shares is after the conversion 302,035,036.The conversions of shares were registered in the Trade Register on February 22, 2021. The converted shares will be listed on the Nasdaq Helsinki together with the old shares on February 23, 2021.EVLI BANK PLCJuho...

EVLI PANKKI OYJ:N PÖRSSITIEDOTE 22.2.2021 KLO 13.15 (EET/EEST)Evli Pankki Oyj:n hallitus on kokouksessaan 22.1.2021 hyväksynyt osakkeenomistajan pyynnön 7.600 A-osakkeen muuntamisesta B-osakkeiksi yhtiöjärjestyksen 4 §:n nojalla.Muunnon jälkeen Evli Pankin A-osakkeiden määrä on yhteensä 14.627.664 ja B-osakkeiden määrä on yhteensä 9.481.756 osaketta. Evli Pankki Oyj:n osakkeiden kokonaismäärä pysyy ennallaan 24.109.420 kappaleessa. Yhtiön osakkeiden tuottama äänimäärä on muunnon jälkeen yhteensä 302.035.036.Osakkeiden muunto on rekisteröity kaupparekisteriin 22.2.2021. Muunnetut osakkeet tulevat julkisen kaupankäynnin kohteeksi Nasdaq Helsingissä yhdessä vanhojen osakkeiden kanssa 23.2.2021 alkaen.EVLI PANKKI OYJJuho MikolaTalousjohtajaLisätietoja: Daniela Wahlberg, senioriasiantuntija, viestintä, Evli Pankki Oyj, p. +358 50 401 7714,...

VIRGINIA BEACH, Va., Feb. 22, 2021 (GLOBE NEWSWIRE) — Armada Hoffler Properties, Inc. (NYSE: AHH) today announced that its Board of Directors has reaffirmed the Company’s commitment to leadership in corporate governance practices by adopting an amendment to the Company’s bylaws to implement a “proxy access” provision.Proxy access enables eligible long-term stockholders to nominate and include their own director nominees in the Company’s proxy materials, along with the candidates nominated by the Company’s Board of Directors. With the adoption of this bylaw amendment, a stockholder, or group of up to 20 stockholders, owning at least 3% of the Company’s outstanding shares of common stock continuously for at least three years, will be able to nominate and include in the Company’s proxy materials eligible director nominees up to the...